Table 1.
Patient characteristics
| Total | Gastric cancer (n = 256) | Colorectal cancer (n = 280) | |
|---|---|---|---|
| Sex | |||
| Male/female | 357/179 | 189/67 | 168/112 |
| Age | |||
| Median (range) | 66 (11–87) | 66 (22–87) | 66 (11–86) |
| ECOG PS | |||
| 0–1/≥ 2 | 450/86 | 204/52 | 246/34 |
| Stage | |||
| Advanced | 433 (81%) | 225 (88%) | 208 (74%) |
| Postoperative recurrence | 103 (19%) | 31 (12%) | 72 (26%) |
| Metastatic sites | |||
| Lymph node | 279 (52%) | 184 (72%) | 95 (34%) |
| Liver | 253 (47%) | 97 (38%) | 156 (56%) |
| Peritoneum | 131 (24%) | 101 (39%) | 60 (21%) |
| Number of metastatic sites | |||
| 0–1/≥ 2 | 233/303 | 113/143 | 120/160 |
| Fluoropyrimidine type | |||
| 5-FU | 262 (49%) | 43 (17%) | 219 (72%) |
| S-1 | 182 (34%) | 178 (70%) | 4 (1%) |
| Capecitabine | 85 (16%) | 32 (12%) | 53 (19%) |
| Others | 7 (1%) | 3 (1%) | 4 (1%) |
| Molecular-targeted drugs | |||
| Trastuzumab | 35 | 35 | 0 |
| Cetuximab/panitumumab | 25 | 0 | 25 |
| Bevacizumab | 116 | 0 | 116 |
| Chemotherapy regimens | |||
| Fluoropyrimidine alone | 69 (13%) | 55 (21%) | 14 (5%) |
| Combination chemotherapy | 467 (87%) | 201 (79%) | 266 (95%) |
| Platinum | 389 | 161 | 228 |
| Irinotecan | 29 | 0 | 29 |
| Taxane | 24 | 24 | 0 |
| Others | 17 | 16 | 1 |
ECOG PS Eastern Cooperative Oncology Group performance status, 5-FU 5-fluorouracil